CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway
Shilong Jiang, Ting Jiang, Hanxue Huang, Xisha Chen, Lanya Li, Zhibin Wang, Jiang-Feng Fei, Chong Liu, Zhaoqian Liu, Yan Cheng
Topics & Concepts
VemurafenibProtein kinase BCancer researchMAPK/ERK pathwayMelanomaPI3K/AKT/mTOR pathwayKinaseSignal transductionMedicinePharmacologyBiologyCell biologyMetastatic melanomaMelanoma and MAPK PathwaysCellular Mechanics and InteractionsPeptidase Inhibition and Analysis